Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders.
Haemostatic efficacy and pharmacokinetic analysis of solvent/detergent (S/D) treated, virus inactivated plasma (Octaplas, Germany) was evaluated in eight patients with hereditary factor VII, X and XI deficiency and in three patients with acquired coagulation disorders due to liver disease. The patients received the S/D plasma for treatment of haemarthrosis, menorrhagia or before surgical procedures. In all the patients the S/D plasma was sufficient to prevent or stop bleeding. Side effects included urticaria (one patient) and moderate anaphylactoid reaction (one patient). No evidence of plasma-born viral infections was observed up to 12 months after the treatment (95% confidence limits 0-22%). Calculated mean half-life of coagulation factors VII, X and XI was 4.36 h, 49.21 h and 44.5 h, respectively, similar to that observed with fresh-frozen plasma. Because of retained coagulation factor integrity and improved viral safety, S/D plasma could be considered a superior alternative to standard fresh-frozen plasma.
Inbal
A
A
Haematology Unit, Beilinson Medical Centre, Petah Tiqva, Israel.
Epstein
O
O
Blickstein
D
D
Kornbrot
N
N
Brenner
B
B
Martinowitz
U
U
D000328:Adult; D000368:Aged; D001778:Blood Coagulation Disorders / Q000235:genetics / Q000628:therapy*; D003902:Detergents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010949:Plasma / Q000187:drug effects*; D012997:Solvents
D003902:Detergents; D012997:Solvents